We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biohaven’s ALS Treatment Delayed by Complete Response Letter
Biohaven’s ALS Treatment Delayed by Complete Response Letter
Biohaven Pharmaceuticals’ application for an amyotrophic lateral sclerosis (ALS) med drew a complete response letter from the FDA, who cited issues with the company’s use of an API made by an Indian drugmaker warned last year for repeat violations.